Overview

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Lenvatinib